Curetis Appoints Christopher M. Bernard as Chief Executive Officer of Newly-Formed U.S. Subsidiary
– Former Chief Commercial Officer of Epic Sciences brings valuable experience in sales, marketing and commercialization of in-vitro diagnostic platforms
Amsterdam, the Netherlands, and Holzgerlingen, Germany, July 5, 2016 — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that Christopher M. Bernard has been appointed to the newly-created role of President and Chief Executive Officer of the Company’s North American subsidiary Curetis USA, Inc., effective immediately. He will be responsible for the development of the new subsidiary based in San Diego, CA, and will lead the marketing and sales initiatives for Curetis in the U.S.
Curetis USA, Inc. was founded to drive the future development and sales of the Company’s Unyvero Platform in North America. The Company recently announced completion of enrollment in the U.S. FDA trial of Unyvero for the detection of lower respiratory tract infections. Curetis plans to submit the Unyvero LRT55 Cartridge for FDA clearance by the end of 2016, with potential clearance and commercial launch targeted for the first half of 2017.
“We are pleased to have Chris join Curetis as the CEO of our U.S. subsidiary,” commented Oliver Schacht, PhD, CEO of Curetis N.V. “He is a highly accomplished executive with proven ability to develop successful sales and marketing strategies, drive growth for emerging companies, manage operations and deliver on key strategic, commercial and operational objectives. He is an important addition to the leadership team at Curetis and will play a critical role in enhancing the Company’s growing global presence by establishing and leading its U.S. subsidiary, based in San Diego.”
Mr. Bernard joins Curetis with more than 22 years of diagnostics, biopharmaceutical and translational research industry experience, including roles in executive management, strategic development, product commercialization, marketing and sales. Prior to joining Curetis, Mr. Bernard served as Chief Commercial Officer of Epic Sciences, developer of one of the few commercially available platforms that can identify circulating tumor cells in the blood. In this role, Mr. Bernard was responsible for the expansion of Epic’s technology in collaboration with pharmaceutical and biotech companies and leading cancer research centers and the commercialization of Epic’s independent and companion diagnostic products.
Prior to joining Epic Sciences, Mr. Bernard worked at Metabolon, Inc. as an Officer and Senior Vice President, Sales and Marketing, where he rebuilt the company’s Metabolytics business, a business-to-business biochemical profiling service responsible for the company’s total sales at the time. Prior to Metabolon, he served as Vice President, Sales and Marketing and as an Officer of Abaxis, Inc., directing the sales and marketing efforts for the company’s point-of-care diagnostic chemistry platform, Piccolo Xpress®. Mr. Bernard began his career at Cytyc Corporation (Hologic, Inc.), ultimately becoming the regional business director where he was responsible for growth in sales and management of a portfolio of diagnostic products, including ThinPrep® Pap Test and Imager, and NovaSure® endometrial ablation.
Mr. Bernard received a B.A. in Psychobiology from Hiram College, Ohio, where he is a current board member of the Center for Entrepreneurship.
“Curetis is a cutting-edge molecular diagnostics company with tremendous opportunity,” said Mr. Bernard. “I am very excited by this opportunity to lead Curetis USA and support the planned North American commercialization of the Unyvero platform. I look forward to working with Curetis’ outstanding executive team and board to advance the company and position it for further success.”
He added: “This is an exciting as well as strategically important time to be joining Curetis. Once FDA clearance is accomplished, the Unyvero System will make an immediate impact in U.S. hospitals in two key areas: lower respiratory tract infections and antibiotic resistance. In the U.S., there is a death every 10 minutes due to pneumonia, and respiratory infections are the second leading cause of hospitalizations. Coupled with increasing global concern around super bugs that are resistant to standard antibiotics, this makes the timing of a U.S. launch for Curetis ideal.”
CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero product which may be sold at some future point in time in the U.S. have not yet been established.
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering many countries across Europe, the Middle East and Asia.
For further information, please visit www.curetis.com.
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
International Media & Investor Inquiries
Dr. Ludger Wess / Ines-Regina Buth
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Tel. +1 646 536 7012